NEWS: 公告在東京證券交易所JASDAQ標準市場新上市


Pegcetacoplan (APL-2) - 新藥的考察與市場預測:2030年

PEGCETACOPLAN (APL-2)- Emerging Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 973301
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 10個工作天內
Pegcetacoplan (APL-2) - 新藥的考察與市場預測:2030年 PEGCETACOPLAN (APL-2)- Emerging Drug Insight and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 60 Pages


本報告提供主要7個國家 (美國,德國,法國,義大利,西班牙,英國,日本) 市場上Pegcetacoplan (APL-2) 調查分析,提供產品詳細內容與未來市場評估相關的系統性資訊。


第1章 醫藥品概要

  • 產品詳細內容
  • 作用機制
  • 用法·用量
  • 研究開發活動
    • 臨床開發
    • 安全性和有效性
  • 其他開發活動

第2章 市場評估

  • 主要7個國家 (7MM) 市場分析
  • 美國市場
  • 德國市場
  • 法國市場
  • 義大利市場
  • 西班牙市場
  • 英國市場
  • 日本市場

第3章 SWOT分析

第4章 分析師的見解

第5章 市場競爭企業

第6章 其他新藥

第7章 附錄

第8章 報告購買選擇

Product Code: DIDM0102

"PEGCETACOPLAN (APL-2)- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Geographic Atrophy in 7 Major Markets. A detailed picture of the PEGCETACOPLAN (APL-2) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

Pegcetacoplan is an investigational, targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. Apellis is evaluating pegcetacoplan in several clinical studies including paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy (GA), and C3 glomerulopathy. Pegcetacoplan was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of PNH and the treatment of GA.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around PEGCETACOPLAN (APL-2).
  • The report contains forecasted sales for PEGCETACOPLAN (APL-2) till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Geographic Atrophy.
  • The report also features the SWOT analysis with analyst insights and key findings of PEGCETACOPLAN (APL-2).


The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PEGCETACOPLAN (APL-2) Analytical Perspective by DelveInsight

  • In-depth PEGCETACOPLAN (APL-2) Market Assessment

This report provides a detailed market assessment of PEGCETACOPLAN (APL-2) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • PEGCETACOPLAN (APL-2) Clinical Assessment

The report provides the clinical trials information of PEGCETACOPLAN (APL-2) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Geographic Atrophy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence PEGCETACOPLAN (APL-2) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Geographic Atrophy are giving market competition to PEGCETACOPLAN (APL-2) and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of PEGCETACOPLAN (APL-2).
  • Our in-depth analysis of the forecasted sales data of PEGCETACOPLAN (APL-2) from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PEGCETACOPLAN (APL-2).

Key Questions:

  • Which company is developing PEGCETACOPLAN (APL-2) along with the phase of the clinical study?
  • What is the technology utilized in the development of PEGCETACOPLAN (APL-2)?
  • What is the product type, route of administration and mechanism of action of PEGCETACOPLAN (APL-2)?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PEGCETACOPLAN (APL-2) development?
  • What are the key designations that have been granted to PEGCETACOPLAN (APL-2)?
  • What is the forecasted market scenario of PEGCETACOPLAN (APL-2)?
  • What is the history of PEGCETACOPLAN (APL-2) and what is its future?
  • What is the forecasted sales of PEGCETACOPLAN (APL-2) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to PEGCETACOPLAN (APL-2)?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1 PEGCETACOPLAN (APL-2), Description
  • Table 2 PEGCETACOPLAN (APL-2), Clinical Trial Description
  • Table 3 PEGCETACOPLAN (APL-2), 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of PEGCETACOPLAN (APL-2)
  • Figure 2 Patent Details, PEGCETACOPLAN (APL-2)
  • Figure 3 PEGCETACOPLAN (APL-2), 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 PEGCETACOPLAN (APL-2), US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 PEGCETACOPLAN (APL-2), EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 PEGCETACOPLAN (APL-2), Japan Market Size from 2020 to 2030 (in Millions USD)